SPARQL
Query
Update
Search
Quick
Advanced
Co-occurrence
RelFinder
About
Sources
Admin
System Info
Repository Management
Search Configuration
Sources
16763642
Source:
http://linkedlifedata.com/resource/pubmed/id/16763642
Search
Subject
(
44
)
Predicate
Object
All
Download in:
JSON
RDF
N3/Turtle
N-Triples
Switch to
Custom View
Named Graph
All
UniProt
NCBIGene
DrugBank
ClinicalTrials
UMLS
PubMed
Mappings
MentionedEntities
Language
All
English
Español
Português
Français
Deutsch
Русский
日本語
Български
Inference
Explicit and implicit
Explicit only
Implicit only
Statements in which the resource exists as a subject.
Predicate
Object
rdf:type
pubmed:Citation
lifeskim:mentions
umls-concept:C0008976
,
umls-concept:C0162488
,
umls-concept:C0936223
,
umls-concept:C1518823
pubmed:issue
6
pubmed:dateCreated
2006-6-9
pubmed:language
eng
pubmed:journal
http://linkedlifedata.com/resource/pubmed/journal/101226508
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Hormonal
,
http://linkedlifedata.com/resource/pubmed/chemical/Prostate-Specific Antigen
,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1743-4270
pubmed:author
pubmed-author:WardJohn FJF
pubmed:issnType
Print
pubmed:volume
3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
310-1
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:16763642-Adult
,
pubmed-meshheading:16763642-Aged
,
pubmed-meshheading:16763642-Aged, 80 and over
,
pubmed-meshheading:16763642-Antineoplastic Agents, Hormonal
,
pubmed-meshheading:16763642-Clinical Trials, Phase II as Topic
,
pubmed-meshheading:16763642-Drug Resistance, Neoplasm
,
pubmed-meshheading:16763642-Humans
,
pubmed-meshheading:16763642-Male
,
pubmed-meshheading:16763642-Middle Aged
,
pubmed-meshheading:16763642-Neoplasm Metastasis
,
pubmed-meshheading:16763642-Prostate-Specific Antigen
,
pubmed-meshheading:16763642-Prostatic Neoplasms
,
pubmed-meshheading:16763642-Randomized Controlled Trials as Topic
,
pubmed-meshheading:16763642-Treatment Outcome
,
pubmed-meshheading:16763642-Tumor Markers, Biological
pubmed:year
2006
pubmed:articleTitle
Can PSA velocity serve as a surrogate endpoint in trials of hormone-refractory, metastatic prostate cancer?
pubmed:affiliation
Nevada Cancer Institute, Las Vegas, NV 89135, USA. jward@nvcancer.org
pubmed:publicationType
Journal Article
,
Comparative Study
,
Meta-Analysis